Myriad Genetics
MYGN
203 hedge funds and large institutions have $519M invested in Myriad Genetics in 2026 Q1 according to their latest regulatory filings, with 33 funds opening new positions, 75 increasing their positions, 68 reducing their positions, and 48 closing their positions.
17% more call options, than puts
Call options by funds: $97K | Put options by funds: $83K
10% more repeat investments, than reductions
Existing positions increased: 75 | Existing positions reduced: 68
4.76% less ownership
Funds ownership: 98.94% → 94.18% (-4.8%)
8% less funds holding
Funds holding: 221 → 203 (-18)
9% less capital invested
Capital invested by funds: $568M → $519M (-$48.7M)
31% less first-time investments, than exits
New positions opened: 33 | Existing positions closed: 48
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Acadian Asset Management
Boston,
Massachusetts
|
+$6.89M |
| 2 |
HF
HRT Financial
New York
|
+$6.86M |
| 3 |
Jane Street
New York
|
+$5.98M |
| 4 |
Marshall Wace
London,
United Kingdom
|
+$5.63M |
| 5 |
GCM
Glenview Capital Management
New York
|
+$4.3M |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
BlackRock
New York
|
-$33.4M |
| 2 |
State Street
Boston,
Massachusetts
|
-$8.04M |
| 3 |
Walleye Capital
New York
|
-$4.16M |
| 4 |
RA
Royce & Associates
New York
|
-$3.72M |
| 5 |
Dimensional Fund Advisors
Austin,
Texas
|
-$2.86M |
MYGN Hedge Fund Activity: Q1 2026 in Review
203 of the 8,184 institutional investors tracked by Wall St. Rank reported a position in Myriad Genetics (MYGN) for Q1 2026, worth a combined $519M — down 8.6% from $568M a quarter earlier.
Sellers outnumbered buyers: 48 funds closed out of MYGN and 33 opened new positions — a net loss of 15 holders — while 68 trimmed existing stakes and 75 added.
The largest buyer was Acadian Asset Management, adding an estimated $6.89M. The largest seller was BlackRock, cutting an estimated $33.4M.
- 203 institutional investors held Myriad Genetics (MYGN) as of Q1 2026, down from 221 in Q4 2025.
- Funds reported $519M of Myriad Genetics stock for Q1 2026, down 8.6% quarter-over-quarter.
- 33 funds opened new Myriad Genetics positions in Q1 2026 and 48 closed out, a net change of -15 holders.
- The largest Myriad Genetics buyer in Q1 2026 was Acadian Asset Management, an estimated $6.89M added.
- The largest Myriad Genetics seller in Q1 2026 was BlackRock, an estimated $33.4M sold.
Based on aggregated 13F filings for Q1 2026.